Literature DB >> 2397204

Kinetic characterization of two active mutants of placental ribonuclease inhibitor that lack internal repeats.

F S Lee1, B L Vallee.   

Abstract

Human placental ribonuclease inhibitor (PRI), a 50-kDa tight-binding inhibitor of angiogenin and pancreatic ribonuclease, consists predominantly of 7 internal repeats, each 57 residues long. Repeats 3 plus 4 (residues 144-257) or repeat 6 (residues 315-371) can be deleted to give mutant proteins, PRI delta 3-4 and PRI delta 6, respectively, that retain inhibitory activity [Lee, F. S., & Vallee, B. L. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 1879-1883]. We describe here the isolation and characterization of these two active mutant proteins. Both inhibit the enzymatic activities of either angiogenin or bovine pancreatic ribonuclease A (RNase A) with a 1:1 stoichiometry, and the mode of inhibition of RNase A by either is competitive. PRI delta 3-4 binds to angiogenin and RNase A with Ki values of 0.72 and 170 pM, respectively The corresponding values for PRI delta 6 are 22 and 43 pM, respectively. Since recombinant PRI to angiogenin and RNase A with Ki values of 0.29 and 68 fM, respectively, deletion of repeats 3 plus 4 weakens both interactions 2500-fold while deletion of repeat 6 weakens them 76,000- and 630-fold, respectively. Therefore, either the deletion of these repeats has altered the conformation of the angiogenin/RNase binding site in PRI or the deleted repeats contribute directly to the binding site, or both. In addition, the tighter binding to angiogenin versus RNase A seen with native PRI has been preserved in PRI delta 3-4 but has been almost completely abolished in PRI delta 6.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2397204     DOI: 10.1021/bi00480a012

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.

Authors:  A C Papageorgiou; R Shapiro; K R Acharya
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.

Authors:  C Z Chen; R Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

3.  Purification and characterization of truncated ribonuclease inhibitor.

Authors:  J Hofsteenge; A Vincentini; S R Stone
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

4.  Selective abolition of pancreatic RNase binding to its inhibitor protein.

Authors:  Kapil Kumar; Michael Brady; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-17       Impact factor: 11.205

Review 5.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

6.  Interaction of semisynthetic variants of RNase A with ribonuclease inhibitor.

Authors:  U Neumann; J Hofsteenge
Journal:  Protein Sci       Date:  1994-02       Impact factor: 6.725

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.